Compare Globus Medical Inc. Class A Common Stock (GMED) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs iShares MBS ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while iShares MBS ETF trades at $89.99 (market cap $35.58B). The key difference: iShares MBS ETF is far larger — about 3.5× Globus Medical Inc. Class A Common Stock's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and iShares MBS ETF for 97 Days on average.
| GMED | MBB | |
|---|---|---|
Market Cap | $10.25B | $35.58B |
Volume | 1,108,124 | 3,918,815 |
Sector | Health | Fixed Income |
52-Week High | $96.82 | $96.91 |
52-Week Low | $58.33 | $89.09 |
Typical Hold Time | 0 Days | 97 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
MBB trades at $90.00 with minimal daily movement (+0.19%). Technical indicators signal bearish momentum with RSI at overbought levels and moving averages trending downward. Recent news highlights significant short interest growth (98.3% increase in September 2026) and concerns about intermediate duration risk amid potential rate hikes. The ETF faces pressure from rising rates while maintaining consistent dividend distributions.
The outlook remains cautious given the bearish technical setup and interest rate sensitivity. While institutional buying provides some support, the combination of high short interest and duration risk creates headwinds. Investors should weigh the steady income against potential price depreciation in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
